Results

Total Results: 6,952 records

Showing results for "weeks".

201. On the CUSP: Stop BSI: evaluating the relationship between central line–associated bloodstream infection rate and patient safety climate profile. | PSNet
     psnet.ahrq.gov/issue/cusp-stop-bsi-evaluating-relationship-between-central-line-associated-bloodstream-infection
     January 30, 2013 - Citation Text: Weaver SJ, Weeks K, Pham JC, et al. … Facebook Twitter Linkedin Copy URL November 12, 2014 Weaver SJ, Weeks … Copy URL Cite Citation Citation Text: Weaver SJ, Weeks

202. The effectiveness of root cause analysis: what does the literature tell us? | PSNet
     psnet.ahrq.gov/issue/effectiveness-root-cause-analysis-what-does-literature-tell-us
     February 11, 2013 - Citation Text: Percarpio KB, Watts V, Weeks WB. … Twitter Linkedin Copy URL January 11, 2017 Percarpio KB, Watts V, Weeks … Cite Citation Citation Text: Percarpio KB, Watts V, Weeks

203. What do we know about financial returns on investments in patient safety? A literature review. | PSNet
     psnet.ahrq.gov/issue/what-do-we-know-about-financial-returns-investments-patient-safety-literature-review
     April 06, 2011 - Citation Text: Schmidek JM, Weeks WB. … Facebook Twitter Linkedin Copy URL June 17, 2010 Schmidek JM, Weeks … Copy URL Cite Citation Citation Text: Schmidek JM, Weeks

204. Screening for Gestational Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/9K4QQKvhXZNJLCxNX3FkZm
     May 01, 2008 - accompanying systematic re- view of articles published since the 2003 review for screening after 24 weeks … Additional searches were performed for evi- dence published from 1966 to 1999 on screening before 24 weeks … Benefits of Detection and Early Treatment Screening before 24 Weeks’ Gestation The evidence is poor … Time of Screening Most screening is conducted between 24 and 28 weeks’ gestation. … The USPSTF identified no RCTs for screening and treatment before 24 weeks’ gestation.

205. Final Recommendation Statement: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication
     September 28, 2021 - However, manifestations of preeclampsia may take days or weeks to resolve, with some cases presenting … Low-dose aspirin use should be initiated after 12 weeks of gestation (studies most often initiated before … 20 weeks of gestation). … of gestation, but initiation ranged from at 11 to 32 weeks of gestation and generally continued until … FDA Drug Safety Communication: FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later

206. TeamSTEPPS® Diagnosis Improvement: Diagnostic Journey of Mr. Kane (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/teamstepps-program/dx-improvement/dx-journey-presenter-notes.pdf
     June 02, 2025 - [Ben Kane, son]: Four weeks after that appointment with Dr. … Slide 13 Over the Next 6 Weeks [Ben Kane, son]: Over the next 6 weeks, Dad did a lot of things. … Slide 15 Biopsy Results [Ben Kane, son]: A few weeks after the biopsy, I remember that Dad was still … Slide 18 4 weeks after PCP, Mr. … Elliott Over the Next 6 Weeks CT Scan Results Biopsy Results Oncologist - Dr.

207. Cannabis-App-F1-F4-Tables-Surveillance-Report-2 0 0 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f1-f4-tables-surveillance-report-2_0_0.xlsx
     May 29, 2025 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

208. Cannabis-2023-Surv-Rep-1-App-F (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-1-app-F.xlsx
     January 01, 2023 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

209. Cannabis-2022-Surv-Rep-4-Tables-F1-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-tables-F1-4.xlsx
     January 01, 2022 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

210. Cannabis-2023-Surv-Rep-4-Tables-E-1-E-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-tables-E-1-E-4.xlsx
     January 01, 2023 - mg per 100 mcl oromucosal spray (Sativex) titrated to max 6 doses with stable dosing for further 3 weeks … , crossover to ibuprofen 400 mg/day for 8 weeks 0.5 mg/day Ibuprofen 400 mg/day for 8 weeks, crossover … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone … , cross over to ibuprofen 400 mg/day for 8 weeks Ibuprofen 400 mg/day for 8 weeks, crossover to nabilone

211. Cer-238-Cervical-Ripening-Appendix-E-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-238-cervical-ripening-appendix-e-1.xlsx
     January 01, 2009 - 42 weeks with inpatient cervical ripening if necessary. … -If they passed 42 weeks of gestation, then patients were admitted for induction. … and 4 days and 41 weeks. … -Subjects were instructed to return at 40 and 41 weeks for routine reassessments. … Fetal heart rate monitoring was done only if clinically indicated at 40 weeks and routinely at 41 weeks

212. AHRQ's Safety Program for Nursing Homes: On-Time Pressure Ulcer Prevention | Agency for Healthcare Research and Quality
     www.ahrq.gov/patient-safety/settings/long-term-care/resource/ontime/pruprev/exercises5.html
     December 01, 2017 - Viewing the trends over the last 4 weeks, which category has: Shown no improvement over 4 weeks?

213. Cer-276-Ocd-Appendix-H (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-276-ocd-appendix-h.xlsx
     January 01, 2023 - ES 95% CI SE P-Value Favors Strength 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks (post-treatment … 0.35  -1.79 to 2.49 0.75 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks … 7-11 Strength unclear (Continuous predictors; P<0.05) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks … 0.15 -0.45 to 0.74 0.631 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks … B 0.06 -0.01 to 0.13 0.83 NS Neutral (Nonsignificant) 25721185 Torp 2015 GPA NordLOTS, stage 1 14 weeks

214. Cesarean Delivery for Nulliparous (NTSV) Women (Appropriate Use) (pdf file)
     www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
     March 01, 2016 - This measure is aimed at assessing the number of cesarean deliveries at 37 weeks or after, for women … who gave birth during a 12-month period to a live singleton in vertex presentation at or beyond 37 weeks … who gave birth during a 12-month period to a live singleton in vertex presentation at or beyond 37 weeks … of gestation (6.3 percent at 37 weeks and 29.5 percent at 38 weeks) and 49.1 percent at 39 weeks of … of gestation (6.3 percent at 37 weeks and 29.5 percent at 38 weeks) and 49.1 percent at 39 weeks of

215. SOPS Research Datasets | Agency for Healthcare Research and Quality
     www.ahrq.gov/sops/databases/research-datasets.html
     May 01, 2024 - Typically, hospitals are given 12 weeks to provide written authorization for the release of their data … Once written authorization is received, it typically takes another 12 weeks to release the identifiable

216. A Theory-Based Patient Portal eLearning Program for Older Adults with Chronic Illnesses - Final Report (pdf file)
     digital.ahrq.gov/sites/default/files/docs/citation/r21hs024739-nahm-final-report-2019.pdf
     January 01, 2019 - Participants were recruited online, and data were collected at baseline, 3 weeks, and 4 months. … At 3 weeks, the intervention group showed significantly greater improvement than the control group in … All participants completed an online follow-up survey at the end of 3 weeks. … The significance of the group-by-time interaction tested whether the change (baseline to 3 weeks or … (The control group had access to T-PeP for three weeks upon completion of the study.)

217. Appendix B. Clinical Materials to Share With Primary Care Providers (continued) | Agency for Healthcare Research and Quality
     www.ahrq.gov/es/patient-safety/settings/hospital/resource/nicu/packet/apb3.html
     December 01, 2013 - , iron, anti-infective properties (e.g., IgA), and neuroprotective properties for approximately 4-6 weeks … Infants <34 weeks or BW<1800g should receive a multivitamin (1mL/day) and an iron supplement (2 mg/kg … Evaluate at 2-4 weeks post-discharge and as needed thereafter: weight, length, FOC, serum phosphorous … If tube comes out before tract has formed (6-12 weeks), must be reinserted by a physician. … Most significant growth occurs between 36-40 weeks postmenstrual age.

218. Appendix B. Clinical Materials to Share With Primary Care Providers (continued) | Agency for Healthcare Research and Quality
     www.ahrq.gov/patient-safety/settings/hospital/resource/nicu/packet/apb3.html
     December 01, 2013 - , iron, anti-infective properties (e.g., IgA), and neuroprotective properties for approximately 4-6 weeks … Infants <34 weeks or BW<1800g should receive a multivitamin (1mL/day) and an iron supplement (2 mg/kg … Evaluate at 2-4 weeks post-discharge and as needed thereafter: weight, length, FOC, serum phosphorous … If tube comes out before tract has formed (6-12 weeks), must be reinserted by a physician. … Most significant growth occurs between 36-40 weeks postmenstrual age.

219. 059-Nursing-Protocol-Nasal-Mupirocin (doc file)
     www.ahrq.gov/sites/default/files/wysiwyg/hai/tools/mrsa/059-nursing-protocol-nasal-mupirocin.docx
     October 01, 2024 - · High rate of MRSA and MSSA eradication for the first 2 weeks after 5-day application. … , for 5 days or until discharge (if prior to 5 days). · If patient is in the unit for longer than 2 weeks

220. Raising the barcode: improving medication safety behaviours through a behavioural science-informed feedback intervention. A quality improvement project and difference-in-difference analysis. | PSNet
     psnet.ahrq.gov/issue/raising-barcode-improving-medication-safety-behaviours-through-behavioural-science-informed
     November 01, 2023 - BCMA use increased during the first six weeks of the intervention then plateaued during the final 12 … weeks.